Xenon ends development of acne drug

27 March 2017

Shares in Canadian biotech Xenon Pharmaceuticals (Nasdaq: XENE) have taken a nosedive following the news that a Phase II study of XEN801 in moderate to severe facial acne failed to meet its primary endpoint.

Xenon’s share price closed 52% down on Friday compared to the previous close, and on Monday it was down a further 2% within two hours of trading, at $4.55.

Results from the trial showed that XEN801, a topical stearoyl Co-A desaturase-1, or SCD1 inhibitor, did not demonstrate a statistically-significant difference from vehicle placebo in its primary endpoint of the percentage change in total inflammatory and non-inflammatory lesion count from baseline to week 12.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK